Lifecome Biochemistry Co.,Ltd.

Shenzhen Stock Exchange 002868.SZ

Lifecome Biochemistry Co.,Ltd. Price to Earnings Ratio (P/E) on January 27, 2025: -10.38

Lifecome Biochemistry Co.,Ltd. Price to Earnings Ratio (P/E) is -10.38 on January 27, 2025, a 19.65% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Lifecome Biochemistry Co.,Ltd. 52-week high Price to Earnings Ratio (P/E) is -7.82 on September 18, 2024, which is 24.63% above the current Price to Earnings Ratio (P/E).
Lifecome Biochemistry Co.,Ltd. 52-week low Price to Earnings Ratio (P/E) is -14.44 on March 11, 2024, which is -39.12% below the current Price to Earnings Ratio (P/E).
Lifecome Biochemistry Co.,Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -10.75.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Shenzhen Stock Exchange: 002868.SZ

Lifecome Biochemistry Co.,Ltd.

CEO	Mr. Zhongshou Bao
IPO Date	May 3, 2017
Location	China
Headquarters	No. 19,Nanpu Ecological Industrial Park
Employees	992
Sector	Consumers Staples
Industries Personal Care Biotechnology Cleaning Supplies Cosmetics Fertilizers Pet Food Pharmaceuticals Plastics

Description

Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It primarily offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, natamycin products, etc. The company was founded in 2003 and is based in Pucheng, China.

Key trends

Past 5 years